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Overexpression of JARID1B promotes differentiation
via SHIP1/AKT signaling in human hypopharyngeal
squamous cell carcinoma
Jisheng Zhang*,1,5, Xiaofei An2,5, Yafei Han1, Rui Ma3, Kun Yang1, Lu Zhang1, Jingwei Chi1, Wei Li1, David Llobet-Navas4, Yan Xu*,3 and
Yan Jiang*,1
Histone H3 (H3K4) demethylase JARID1B is aberrantly upregulated in many types of tumor and has been proposed to function as
oncogene. Here we show that JARID1B is elevated in moderate and high-differentiated human hypopharyngeal squamous cell
carcinoma (HPSCC) compared with low-differentiated HPSCC. Overexpression of JARID1B in FaDu cells increased epithelial
differentiation marker K10 expression and inhibited cell proliferation. JARID1B and K10 mRNA expression is high correlated in
HPSCC patients. Mechanistically, we found JARID1B directly bound to PI3K/AKT signaling inhibitor SHIP1 gene promoter and
decreased SHIP1 gene expression. Activation of downstream AKT resulted in increased β-catenin signaling, by which promoted
target genes Fra-1 and Jun, together with other AP-1 transcription factors, leading to K10 expression. Forced expression of SHIP1
rescued JARID1B-induced phenotypes on FaDu cell differentiation and proliferation. Taken together, our findings provide first
evidence that elevated expression of JARID1B has a critical role in promoting HPSCC differentiation and inhibiting proliferation,
suggesting JARID1B may function as a tumor suppressor in squamous cell cancers and implying a novel important therapeutic
strategy of HPSCC.
Cell Death and Disease (2016) 7, e2358; doi:10.1038/cddis.2016.262; published online 1 September 2016
Hypopharyngeal squamous cell carcinomas (HPSCC) have
the worst survival though it only represents 3–4% of all head
and neck cancers.1 Studies demonstrated that early-stage
HPSCC has a 71% 5-year survival rate.2 However, once up to
advanced stage 5-year survival rate could be as low as 16%
and as high as 47%.3,4 HPSCC usually does not give rise to
symptoms until late in the course of the disease. To date,
treatment of HPSCC is still a big challenge and less attention
has been received, in part because of its low incidence and
clinical difficulty. HPSCC can be treated by surgery on the
early stage, whereas a large part of patients was found to have
late-stage cancer at diagnosis.5 In recent years, instead of
surgical excision non-surgical treatments have been used to
largely preserve organ function. It has been reported that there
is no significant survival differences between the organ
preservation and surgery arms,6 suggesting the importance
of non-surgical treatment in this type of cancer. Therefore, it is
important and necessary to develop alternative treatment
strategies. Recent decades the growing understanding of
molecular mechanisms involved in the cancer cell prolifera-
tion, differentiation and cell death has led to the development
of multiple targeted therapies with significant clinical benefits.
However, little is known about the mechanisms involved in
progression of HPSCC.
There is emerging evidence for a causal role of aberrant
expression of Jarid1b in human cancer. Jarid1b belongs to
Jarid1 subfamily, which comprises four members, JARID1A
(KDM5A/RBP2), JARID1B (KDM5B/PLU1), JARID1C
(KDM5C/SMCX) and JARID1D (KDM5D/SMCY). They share
a JmjC (catalytic) domain and could demethylase H3K4me3 to
produce histone H3 (H3K4)me2 and/then H3K4me1, resulting
in gene transcription repression upon removal of H3K4me3.
Jaird1b has been reported to be overexpressed in breast
cancer,7–9 lung cancer, bladder cancer,10,11 colorectal
cancer,12 prostate cancer13 and malignant melanoma.14
Jarid1b is upregulated in these cancers and required for
cancer cell proliferation and tumor growth. In breast cancer it
has been reported that the depletion of Jarid1b led to inhibition
of breast cancer cell proliferation and to reduce tumor growth
in xenografts15 or syngeneic mousemammary tumor model.16
Similar results were obtained in lung cancer, bladder cancer
and colorectal tumors. Interestingly, Roesch et al.17 charac-
terized a slowly cycling subpopulation of human melanoma
cells that express high levels of Jarid1b, whereas this
subpopulation cell can give rise to highly proliferative progeny
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with low Jarid1b expression. The dynamic regulation of
Jarid1b expression suggests a new mechanism of Jarid1b-
regulating stem cell-like properties in tumor maintenance.
This JARID1Bhigh subpopulation is enriched upon a variety of
drug treatments, which could be blocked by inhibition of
mitochondrial respiration.14 The phenotypic consequences in
various types of human cancer highlight importance of elevated
Jarid1b expression. However, the mechanisms of Jarid1b
controlling the described phenotypes are not fully understood
yet. It seems that Jarid1b-regulating genes presents cell type-
specific pattern.
Moreover, Jarid1b has an important role in cell differentiation
during development. Jarid1b controls mesenchymal cell fate
into myogenic and osteogenic lineages,18 macrophage19 and
embryonic stem cell (ESC) differentiation.20,21 In luminal breast
tumors overexpressed Jarid1b functions as a luminal lineage-
driving oncogene. High luminal JARID1B activity is correlated
with poor outcome in patients with hormone receptor-positive
breast tumors.22 However, the mechanisms of Jarid1b leading
to the differentiation in tumors remain barely explored.
Here we investigated the function of Jarid1b elevation in
HPSCC. We found that the high/moderate differentiated
HPSCC had high Jarid1b expression compared with low-
differentiated cancer. In FaDu cells overexpressed Jarid1b led
to high expression of K10, which is an epithelial differentiation
marker. The forced expression of JARID1B impaired cell
proliferation, indicating that Jarid1b may function as a
repressor of cancer progression. Mechanistically, our data
showed that Jarid1b downregulated Ship1 and in turn
activated PI3K-AKT pathway. Consequently, β-catenin was
phrosphorlated by AKT and the β-catenin target genes Fra-1
and Jun, together with other AP-1 genes, induced K10
expression. Restoration of Ship1 could rescue the phenotypic
consequences of Jarid1b overexpression. In this study, we
mainly forced expression of Jarid1b to mimic the pathological
process in HPSCC. Our findings reveal a novel function of
Jarid1b in control of the tumor differentiation and may provide
perspective to develop novel therapeutic interventions for
HPSCC and other squamous cell carcinomas.
Results
Jarid1b is overexpressed in the moderate and high-
differentiated HPSCC. It has been reported that Jarid1b is
upregulated in many types of cancer and promotes prolifera-
tion of cancer cells. We first used the RT-qPCR method to
quantify the expression of Jarid1b in HPSCCs compared
with the adjacent normal tissues. Unfortunately, there was
no significant difference owing to the variation of Jarid1b
expression level. Some recent researches have demon-
strated that Jarid1b could be involved in differentiation during
development. To gain the insights into the role of Jarid1b in
the cancer differentiation, we divided all the samples into two
groups according to the pathological differentiation grade
diagnosis. We found that Jarid1b was high expressed in the
moderate and high-differentiated HPSCC compared with the
low-grade samples (Figure 1a). Consistently, the observation
was confirmed by western blot that JARID1B was upregu-
lated compared with the adjacent normal tissue in the
moderate/high-differentiated HPSCC. In addition, K10, a
specific epithelial differentiation marker, was also markedly
elevated in the cancer (Figure 1b). To further examine role of
Jarid1b regarding to differentiation and proliferation, we
Figure 1 Jarid1b is overexpressed in the moderate and high-differentiated HPSCC. (a) Measurement of Jarid1b mRNA expression for the divided groups by quantitative
RT-PCR. L: low-differentiated HPSCC (n= 10), H/M: moderate and high-differentiated HPSCC (n= 24). **Po0.01, Student’s t-test. (b) JARID1B and K10 proteins were detected
by immunoblotting in the H/M-differentiated HPSCC (HPC) and adjacent normal tissue (ANT). (c) Representative images of immunohistochemical staining for JARID1B, K10 and
Ki67 in L and H/M-differentiated human HPSCC. K10 showed no obvious staining in cytoplasm in low-differentiated HPSCC. All scale bars are 100 μm. (d) Quantifications were
provided and showed high JARID1B expression and low Ki67-positive percentage in the H/M HPSCC. **Po0.01, Student’s t-test
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performed the IHC staining against Jarid1b, K10 and Ki67.
Ki67 is an excellent marker to define the proliferation
population and often correlated with the clinical course and
outcomes of cancer. Compared with the low-grade cancer
JARID1B was high expressed in the moderate and high-
differentiated HPSCCs, which displayed strong K10 staining
and low percentage of Ki67 (Figures 1c and d).
Forced expression of Jarid1b leads to FaDu cell differ-
entiation. To assess the potential role of Jarid1b in the
regulation of HPSCC differentiation, Flag-Jarid1b was over-
expressed in FaDu cells, which came from a hypopharyngeal
squamous cell carcinoma. As expected overexpression of
Jarid1b increased K10 mRNA expression level in FaDu cells
(Figure 2a). We tried to explore more epithelial keratin
markers such as K13, but unfortunately we did not find any
other reliable differentiation gene markers. Thus, in this study
we only used K10 as a differentiation marker. Consistent with
RT-PCR results, forced expression of Jarid1b led to elevation
of K10 at protein level. In addition, H3K4me3 was down-
regulated upon Jarid1b expression (Figure 2b). To evaluate
the significance of Jarid1b in control of K10 expression, we
analyzed correlation between these two gene mRNA levels
normalized to adjacent normal tissue in all the 34 HPSCC
samples. High-positive correlation was obtained between
mRNA levels of Jarid1b and K10 (R=0.721, Po0.01),
suggesting that Jarid1b expression level is an important
influential factor for K10 expression in HPSCC (Figure 2c). It
has been well documented that Jarid1b depletion inhibited
cancer cell proliferation. But how the overexpression of
Jarid1b affects cell growth has been ignorable. We over-
expressed Jarid1b or control in FaDu cells and exerted CCK8
assay to measure the cell proliferation. Unexpectedly, upregu-
lation of Jarid1b inhibited FaDu cell proliferation compared with
control (Figure 2d). The results are consistent with IHC
staining, which showed that high-differentiated HPSCCs have
high JARID1B and low Ki67 expression (Figures 1c and d).
These observations suggested that Jarid1b may affect cancer
cell growth via different mechanisms.
Knockdown of Jarid1b represses K10 transcription. Next
we knockdown Jarid1b with shRNA lentivirus to further
validate the role of Jarid1b in control of FaDu cell differentia-
tion. Jarid1b mRNA and protein expression has been
markedly reduced after infection 72 h (Supplementary
Figures S2A and 2e). Compared with control K10 mRNA
expression decreased upon depletion of Jarid1b
(Supplementary Figure S2B). However, K10 protein expres-
sion was undetectable even with long exposure, whereas
much less-loaded HaCaT cells showed a very strong band
(Supplementary Figure S2C). Our results are consistent with
characteristic of poorly differentiated FaDu cell. Finally, CCK8
assay was performed to measure cell proliferation with
Jarid1b depletion. Knockdown with Jarid1b shRNA lentivirus
promoted cell proliferation compared with control (Figure 2e).
β-catenin signaling is activated by overexpression of
Jarid1b. β-catenin (CTNNB1) signaling exerts crucial roles
Figure 2 Forced expression of Jarid1b leads to FaDu cell differentiation. (a) K10 mRNA expression was assessed by RT-qPCR in stable Jarid1b-overexpressing (O/E) FaDu
cells. (b) Protein lysates of FaDu cell-transfected Flag-Jarid1b or control were analyzed for JARID1B, Flag, K10, H3K4me3 and Histone 3(H3) by immunoblotting. (c) Correlation
between Jarid1b gene expression (mRNA) and K10 gene expression (mRNA) in all human HPSCCs (n= 34) based on their gene expression analysis by RT-qPCR. (d) Cell
proliferation was measured by CCK8 assay at indicated time points in Jarid1b or control-overexpressing cells. *Po0.05, **Po0.01, Student’s t-test. (e) Cell proliferation was
measured by CCK8 assay at indicated time points in Jarid1b or control knockdown cells. *Po0.05, Student’s t-test
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in the regulation of cell behaviors such as proliferation,
survival and differentiation. We transiently overexpressed
Flag-Jarid1b or control vector into FaDu cells and pure cell
population was selected by puromycin. The cells were fixed
and immnostained against β-catenin (red) antibody. In contrast
to control cells, which showed cytoplasm and membrane
staining pattern, the Jarid1b O/E cells displayed accumulation
of β-catenin staining in the nucleus and cytoplasm (Figure 3a),
indicating that overexpression of Jarid1b enhances the nuclear
translocation of β-catenin and activates β-catenin signaling. By
western blot higher levels of β-catenin were detected in
Jarid1b-overexpressing cells. Interestingly, Jarid1b selectively
promoted the phosphorylation of β-catenin at S552 but not
S675, implying specific regulation manner of Jarid1b
(Figure 3b). Treatment of β-catenin inhibitors, ICG001 and
XAV-939, repressed K10 expression in stable Jarid1b-
overexpressing cells (Figures 3c and d).
Two AP-1 transcription factors, Fra-1 and Jun, have been
found to be downstream target genes of activated β-catenin.23
In addition, our previous results and others have demon-
strated that Ap-1 is involved in regulating epithelial marker
genes by direct promoter binding.24,25 Indeed, many of AP-1
genes including Jun, Fos, FosB and Fra-1 showed high
expression in the stable Jarid1b-overexpressing cells
(Figure 3e). Moreover, treatment of Tanshinone IIA, which is
thought to abrogate all AP-1 binding to DNA, decreased the
expression of K10 (Figure 3f). These results suggest
that β-catenin may have a critical role in regulating K10
expression.
Overexpression of Jarid1b results in activation of AKT.
As Akt can phosphorylate β-catenin at S552 and promotes
β-catenin nuclear localization,26–28 we tested whether the
upregulation of Jarid1b influences Akt activation. As shown in
Figure 4a, overexpression of Jarid1b led to increase of
phosphorylated AKT though it did not affect the pan-AKT
expression. In stable Jarid1b-overexpressing cells with
adding specific inhibitors of AKT, Perifosine, we found that it
significantly inhibited K10 production at either 5 or 2.5 μm
(Figures 4b and d), suggesting activated AKT is involved in
K10 expression in response to Jarid1b overexpression. Next
we tested the AKT upstream molecule PI3K by its inhibitor,
LY294002, to further validate the promotive effect of
Phosphor-AKT on K10 expression and underlying pathways.
Consequently, we found that at 50 μM concentration
LY294002 could effectively decrease K10 protein level
(Figures 4c and d). In the control cells we got similar results
at transcription level with RT-qPCR though K10 protein
expression was undetectable owing to poor differentiation of
FaDu cells (Supplementary Figures S4A–D). These findings
suggest that PI3K-AKT pathway is required for Jarid1b
driving FaDu cell differentiation.
Ship1 is downregulated upon Jarid1b overexpression.
Theoretically, Jarid1b upregulation leads to transcription
inhibition of its target genes. Thus, we speculated that the
target genes of Jarid1b should be any inhibitors of PI3K-AKT
pathway and Pten or Ship1 could be potential candidates. We
first examined Pten and Ship1 mRNA expression levels by
RT-qPCR. The results demonstrated that at transcription level
Figure 3 β-catenin signaling is activated by overexpression of Flag-Jarid1b. (a) Puromycin selected Jarid1b-overexpressing and control FaDu cells were stained with
β-catenin antibody (red) and counterstained with DAPI, showing that Jarid1b O/E cells displayed nucleus staining pattern compared with control. (b) β-catenin and its two
phosphorylated isoforms, S552 and S675, were detected by immunoblotting in stable Jarid1b O/E or control cells. (c) K10 mRNA expression was analyzed by RT-qPCR upon
treatment of β-catenin inhibitors, ICG001 and (d) XAV-939 and (f) AP-1 inhibitor Tan IIA at indicated concentration in stable Jarid1b O/E cells. (e) Expression of indicated
AP-1 genes was assessed by RT-qPCR in stable Jarid1b O/E and control cells
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Ship1 was substantially downregulated by Jarid1b over-
expression whereas Pten only slightly decreased (Figure 5a).
Chromatin immunoprecipitation (ChIP) assay was performed
to validate whether Jarid1b controls Ship1 transcription by
directly binding SHIP1 gene promoter. We designed five pairs
of primer targeting the promoter and intron 1 of SHIP1 gene
as indicated in Figure 5b. The results demonstrated that Flag-
Jarid1b was enriched at transcription start site (TSS) and
promoter region of SHIP1 gene (Figure 5b). H3K4me3
enrichment also showed a similar pattern in the Jarid1b O/
E cells (Supplementary Figure S5A). Moreover, H3K4me3
enrichment was reduced at SHIP1 gene TSS upon Jarid1b
overexpression (Figure 5b). The results indicate that Jarid1b
controlling Ship1 expression could be associated with its
demethylase function.
Rescue of Jarid1b-overexpressing phenotypes by Ship1
in FaDu cells. We next asked that if overexpression of Ship1
could rescue Jarid1b-induced phenotypes. The results
showed that overexpression of Ship1 could attenuate the
elevation of K10 expression induced by Jarid1b (Figure 5c).
Furthermore, the inhibition of cell growth induced by Jarid1b
got restored by the overexpression of Ship1 (Figure 5d).
Together, the results suggest that Ship1 is the direct target of
Jarid1b to induce FaDu cell differentiation by activating
Ship1-PI3K-Akt pathway.
Discussion
Although Jarid1b overexpression occurs in a wide variety of
cancers, the function of Jarid1b in cancer is not fully under-
stood. Epigenetic mechanisms have been documented as a
critical step in tumorigenesis, progression and metastasis, but
how these epigenetic molecules exactly control the
downstream pathway or whether the phenomenon simply
occurs concomitantly is still underexplored. Here, for the first
time, we uncovered the relevance of Jarid1b, a demethylase of
H3K4me3, in control of squamous cancer cell commitment.
We showed that elevated Jarid1b promotes the HPSCC
differentiation and inhibits cancer cell proliferation. Impor-
tantly, we dissected the molecular mechanisms of this
regulation by showing that Jarid1b could induce K10 expres-
sion by controlling its downstream target gene, Ship1, an
inhibitor of PI3K-AKT pathway (Figure 5e).
Epigenetic modification has a critical role in the main-
tenance of cell fate.29 ESCs, progenitors and cancer stem
cells are characterized by distinct epigenetic features to
maintain the differentiation potential. Among these are an
activate histone mark, H3K4me3, and a repressive mark
H3K27me3, which are largely enriched at the promoter and
mark developmental and lineage-specific genes.30 Our pre-
vious results have showed that removal of Ezh1 and Ezh2, key
Polycomb subunits, from mouse skin leads to remarkable
switch in fate determination in epidermal progenitor cells,
resulting in an increase in the number of lineage-committed
Merkel cells.31 The role of the Jarid1b in controlling cancer cell
commitment is somehow reminiscent of its function in breast
cancer cells, where Jarid1b has also been shown to drive a
luminal transcriptional program.22 Here we provided first
evidence that overexpressed Jarid1b induces cancer differ-
entiation in HPSCC.
It has been reported that Jarid1b functions as an oncogene
in a variety of tumors. The proliferation of cancer cells is
inhibited when depleting Jarid1b. Interestingly, we observed
that overexpression of Jarid1b in FaDu cells could inhibit the
proliferation, which suggests that the function of Jarid1b is
more complicated thanwe thought. Herewemainly ectopically
expressed Jarid1b to investigate the role of Jarid1b, whereas
Figure 4 Overexpression of Jarid1b results in activation of AKT. (a) AKTand Phosphorylated AKTwere detected by immunoblotting in stable Jarid1b O/E or control cells.
(b) K10, AKTand Phosphorylated AKTwere detected by immunoblotting upon the treatment of AKT inhibitor Perifosine and (c) PI3K inhibitor LY294002 at indicated concentration
in stable Jarid1b O/E cells. (d) Quantifications were assessed from three independent experiments showing as fold change versus control
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most of the previous results were obtained by the depletion of
Jarid1b. Epigenetic regulators are ubiquitously expressed and
have a fundamental role in the cells and are involved in cell
cycle dynamics. In hepatocellular carcinoma, gastric cancer
and lung cancer Jarid1a suppresses the expression of CDK
inhibitors p21Cip1, P27Kip1 and P16Ink4a.32–35 In addition,
Jarid1b can repress the cell cycle inhibitor p21Cip1 in a variety
of cell lines.36 In our study we found that the FaDu cell
proliferation can also be inhibited upon the overexpression of
Jarid1b. By dissecting the genetic mechanism, we demon-
strated that Jarid1b promotes differentiation and inhibits
proliferation of FaDu cells by repressing Ship1, a phosphatase
of PIP3. Ectopic expression of Ship1 results in the de-
differentiation and improves the proliferation of differentiated
FaDu cells, indicating that Ship1 is a critical regulator of FaDu
cell differentiation. Our results showed that Jarid1b directly
inactivates Ship1, one of critical regulator of PI3K/AKT
pathway. Concordant inhibition of PI3K/AKT attenuates the
Jarid1b overexpression induced phenotypes, confirming the
importance of Jarid1b repression of Ship1 in promoting FaDu
cell differentiation state. Recently, other investigations have
implied that other members of Jarid1 family serve as tumor
suppressor. Jarid1c is a target gene of von Hippel Lindau
(VHL) tumor suppressor protein. Depletion of Jarid1c accel-
erates tumor growth in VHL-deficient cells.37 Jarid1a has been
described as a binding partner of the retinoblastomatumor
suppressor protein. Jarid1a and Jarid1b contribute to a tumor
suppressor network controlling cellular senescence.38 Jar-
id1d, a male-specific protein, represses invasion-associated
genes MMP1, MMP2, MMP3, MMP7 and Slug in vitro and
in vivo. Low JARID1D level is associated with poor prognosis
in prostate cancer patients.39 We still do not knowwhether this
function of Jarid1b could apply to other cancers or it is heavily
context-dependent. However, this study sheds light on the
importance of Jarid1b as a tumor suppressor at least in
squamous cancers.
Hyperactivation of the PI3K/Akt pathway is a universal tumor
driver which correlated with tumor cellular functions, such as
proliferation, metabolism, invasion, metastasis and survival.
Thus, PI3K signaling could be an important therapeutic target
and several small molecules have been developed to
antagonize activity of the pathway. However, some results
from PI3K/AKT inhibitor trials suggest that deep and sustained
responses to single agents are infrequent. Moreover, Caino
et al.40 have reported that PI3K inhibitors currently in clinic
induce global transcriptional reprogramming in tumors which
Figure 5 Jarid1b promotes FaDu cell differentiation through directly repression of SHIP1 gene. (a) Pten and Ship1 mRNA expression were analyzed by RT-qPCR in Jarid1b
O/E and control cells. (b) ChIP studies on Jarid1b-overexpressing cells showed Jarid1b binding at the SHIP1 promoter region. The scheme indicated the designed primer location
at SHIP1 gene. ChIP-qPCR signal was normalized to experimental control cells infected with control vector. (c) K10 and Flag were detected by immunoblotting in control and
stable Jarid1b-overexpressing FaDu cells transfected with control vector or Ship1-Flag. (d) Cell proliferation was measured by CCK8 assay at indicated time points in Jarid1b and
control or Ship1-Flag co-transfected cells. Jarid1b O/E versus control #APo0.01 #BPo0.05, Jarid1b O/E versus Jarid1b+Ship1 O/E **Po0.01, *Po0.05, Student’s t-test.
(e) Hypothetic model explaining how JARID1B may contribute to HPSCC differentiation
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improve the cell invasion and motility. Therefore, a deeper
understanding of function of PI3K/AKT pathway in diverse
tumors needs to be uncovered. Interestingly, recent report has
shown that all-trans retinoic acid modulates osteogenic
differentiation of mesenchymal stem cells via activating the
PI3K/AKT/β-catenin signaling pathway.41 Here we described
the Jarid1b-Ship1-PI3K network, which is associated with
cancer differentiation grade. The function of Jarid1b-regulatory
network needs to be explored in other types of tumor in the
future studies.
In summary, we described the novel molecular function of
Jarid1b in HPSCC. Our data support a key role for Jarid1b in
improving cell differentiation in HPSCC, where it has been
implicated to function as a tumor suppressor inhibiting cell
proliferation in a Ship1-dependent manner. These new
insights into the role of Jarid1b in tumor may develop potential
treatment strategies for the HPSCC.
Materials and Methods
Cell culture and treatment of inhibitors. FaDu cells were obtained from
ATCC and cultured in DMEM medium with 10% fetal bovine serum and 1%
penicillin/streptomycin. Cells were treated with inhibitors (Selleck, Shanghai, China)
at indicated concentration for 24 h.
Plasmids. Flag-Jarid1b was subcloned into PiggyBac vector and transfected with
help vector. To get the stable and pure Jarid1b-overexpressing cell population we
performed selection with 300 μg/ml of hygromycin until the control cells totally died.
Ship1 was subcloned into pcDNA3-Flag vector. For the immunofluorescence staining
we subcloned Jarid1b-Flag to the pLenti-GIII-CMV-IRES-puro-SV40-GFP vector. To
get pure cell population 2 μg/ml puromycin selection was performed after 24 h of
transfection. Then we changed to new medium after 12 h when the blank control cells
died totally. Visually all the cells were GFP positive under fluorescence microscope
monitor. Jarid1b shRNA plasmids were obtained from JiKai Company. The target
sequences could be found in the Supplementary Table. The plasmids were transfected
with Lipofectamine 3000 into cells following the instructions from the manufacturer.
Western blot analysis. Total cellular or tissue lysates were prepared with 1%
SDS and sonicated to break up DNA. Antibody data can be found in the
Supplementary Table. Each immunoblot was repeated three times containing
samples coming from different cell cultures. The relative intensity of protein bands
was measured with NIH image J software. The blots were developed with Super
Signal Pico substrate (Pierce Biotechnology, Shanghai, China).
Real-time reverse-transcription PCR. Total RNA was extracted from
cells or tissues using RNAiso Plus (Takara D9108, Dalian, Liaoning, China)
following the instructions from the manufacturer. RNA concentration was determined
by Nanodrop. Reverse procedure of cDNA was done using First-strand cDNA
Synthesis kit (Takara RR037A). RT-qPCR was performed using the Roche
Lightcycler480 Real-time PCR System with SYBR green reagents from Takara
(RR820A). Genes were amplified using the primers described in Supplementary
Table. Quantifications were normalized to GAPDH for cell or 18 s rRNA for tissue.
ChIP. ChIP assay was performed as described.24,31 In brief, cells were cross-
linked using 1% formaldehyde for 10 min at room temperature and then rinsed twice
with 1 × PBS. Cells were lysed and sonicated to shear cross-linked DNAs. The
sheared DNA samples were incubated for at least 16 h with 100 μl of Dynal Protein
G magnetic beads (Thermo 1003D, Shanghai, China), which has been preincubated
with antibodies overnight at 4 °C. After ChIP, each sample was washed once in turn
with 1 ml low-salt, high-salt, LiCl and TE buffer for 45 min at 4 °C. Bound complexes
were eluted and reverse cross-linked by overnight incubation at 65 °C in the
presence of RNase A and proteinase K. Finally, the DNA was purified with Phenol/
chloroform/isoamyl alcohol as described.42
Immunohistochemistry. Citrate buffer, pH 6.0, was used to unmask the
epitopes of paraffin-embedded samples. Primary antibodies against Jarid1b and
K10 were incubated overnight at 4 °C. Mean Intensity and the percentage (0–100%)
were quantified by Image-Pro Plus from at least three raw, single-channel gray
scale images, which were conducted at the same condition.
Immunofluorescence. Cells were fixed for 10 min in 4% PFA and blocked for
1 h with blocking buffer. Primary antibody was diluted in blocking solution and
incubated overnight at 4 °C. After washing, secondary antibodies were incubated for
1 h at room temperature. Then DAPI was counterstained for 5 min. Finally the cells
were mounted using anti fade mounting media.
In vitro proliferation assay. In vitro cell proliferation assay was carried out
using a Cell Counting Kit-8 (Dojindo CK04, Shanghai, China) following the
manufacturer’s instructions. In brief, the cells were incubated for 30 min to 2 h after
adding 10 μl CCK8 solutions in 100 μl medium. Then measure the absorbance at
450 nm using a microplate reader.
Statistical analysis. To determine the significance of data obtained from
human samples or cell culture assays, comparisons were made using descriptive
and inferential statistics accompanied by graphs from Prism software program
(GraphPad, La Jolla, CA, USA). Western blot analyses were normalized to β-tublin
protein. In all column bar graphs, mean value± 1 s.d. is presented. For all the
statistics the 0.05 level of confidence was accepted for statistical significance.
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